These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8558491)

  • 1. Response to liposome-encapsulated doxorubicin (TLC D-99) in a dog with myeloma.
    Kisseberth WC; MacEwen EG; Helfand SC; Vail DM; London CL; Keller E
    J Vet Intern Med; 1995; 9(6):425-8. PubMed ID: 8558491
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group.
    Shapiro CL; Ervin T; Welles L; Azarnia N; Keating J; Hayes DF
    J Clin Oncol; 1999 May; 17(5):1435-41. PubMed ID: 10334528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): comparison with doxorubicin and empty liposomes in mice and dogs.
    Kanter PM; Bullard GA; Pilkiewicz FG; Mayer LD; Cullis PR; Pavelic ZP
    In Vivo; 1993; 7(1):85-95. PubMed ID: 8504212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma.
    Braham MV; Deshantri AK; Minnema MC; Öner FC; Schiffelers RM; Fens MH; Alblas J
    Int J Nanomedicine; 2018; 13():8105-8118. PubMed ID: 30555229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model.
    Vail DM; Chun R; Thamm DH; Garrett LD; Cooley AJ; Obradovich JE
    Clin Cancer Res; 1998 Jun; 4(6):1567-71. PubMed ID: 9626479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase-I randomized trial of doxorubicin hydrochloride liposome injection versus Caelyx
    Bhowmik S; Bhowmick S; Maiti K; Chakra A; Shahi P; Rajamannar T
    Leuk Lymphoma; 2018 Jun; 59(6):1478-1481. PubMed ID: 28994344
    [No Abstract]   [Full Text] [Related]  

  • 7. Intermittent single-agent doxorubicin for the treatment of canine B-cell lymphoma.
    Higginbotham ML; McCaw DL; Roush JK; Nietfeld JC; Wilkerson MJ; Reeds K; Burr D
    J Am Anim Hosp Assoc; 2013; 49(6):357-62. PubMed ID: 24051255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors.
    Vail DM; Kravis LD; Cooley AJ; Chun R; MacEwen EG
    Cancer Chemother Pharmacol; 1997; 39(5):410-6. PubMed ID: 9054954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs.
    Kanter PM; Bullard GA; Ginsberg RA; Pilkiewicz FG; Mayer LD; Cullis PR; Pavelic ZP
    In Vivo; 1993; 7(1):17-26. PubMed ID: 8504204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulin A multiple myeloma with cutaneous involvement in a dog.
    Mayer MN; Kerr ME; Grier CK; Macdonald VS
    Can Vet J; 2008 Jul; 49(7):694-702. PubMed ID: 18827847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of methoximorpholino-doxorubicin (FCE 23762) in dogs with spontaneous malignancies.
    Sheafor SE; Couto CG; Ward H; Essinger C; Nicol SJ
    J Vet Intern Med; 2000; 14(1):86-9. PubMed ID: 10668822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of mouse mammary carcinoma development with doxorubicin in liposomes.
    Vaage J; Working P; Uster P
    Int J Cancer; 1998 Jan; 75(1):158-9. PubMed ID: 9426705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors for multiple myeloma in the dog.
    Matus RE; Leifer CE; MacEwen EG; Hurvitz AI
    J Am Vet Med Assoc; 1986 Jun; 188(11):1288-92. PubMed ID: 3721983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of classic Kaposi's sarcoma with liposomal encapsulated doxorubicin.
    Gottlieb JJ; Washenik K; Chachoua A; Friedman-Kien A
    Lancet; 1997 Nov; 350(9088):1363-4. PubMed ID: 9365453
    [No Abstract]   [Full Text] [Related]  

  • 15. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.
    Gabizon A; Martin F
    Drugs; 1997; 54 Suppl 4():15-21. PubMed ID: 9361957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gamma A myeloma in a dog with defective hemostasis.
    Shepard VJ; Dodds-Laffin WJ; Laffin RJ
    J Am Vet Med Assoc; 1972 Apr; 160(8):1121-7. PubMed ID: 5016941
    [No Abstract]   [Full Text] [Related]  

  • 17. Liposomal doxorubicin.
    Tardi PG; Boman NL; Cullis PR
    J Drug Target; 1996; 4(3):129-40. PubMed ID: 8959485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin in sterically stabilized liposomes.
    Lasic DD
    Nature; 1996 Apr; 380(6574):561-2. PubMed ID: 8606781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy.
    Siegal T; Horowitz A; Gabizon A
    J Neurosurg; 1995 Dec; 83(6):1029-37. PubMed ID: 7490617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposome-based intracellular kinetics of doxorubicin in K562/DOX cells.
    Xu DH; Gao JQ; Liang WQ
    Pharmazie; 2008 Sep; 63(9):646-9. PubMed ID: 18819516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.